The study investigates ovarian cancer patients’ responses to platinum-based treatment, focusing on differentiating those who are platinum-resistant from those who are sensitive using metabolomic analysis of urine and serum samples.
By examining metabolites through GC-MS and applying multivariate analysis, researchers identified specific biomarkers associated with platinum resistance, such as 3,4-dihydroxyphenylacetic acid and L-arginine.
The findings reveal significant metabolic pathways involved in these differences, highlighting the relevance of tyrosine metabolism and nitrogen metabolic pathways, which could guide alternative treatment strategies for resistant patients.